PLX

Protalix Biotherapeutics Stock Analysis

AI Rating

Fair
  • Quality5/10
  • Growth↓ 2/10
  • Value↓ 1/10
Protalix Biotherapeutics sales and earnings growth
PLX Growth
Fair
  • Revenue Y/Y↓ -1.23%
  • EPS Y/Y↓ -300.00%
  • FCF Y/Y↓ -284.33%
Protalix Biotherapeutics gross and profit margin trends
PLX Profitability
Neutral
  • Gross margin ↑ 48.80%
  • EPS margin↓ -12.50%
  • ROIC 5Y↓ 8.84%
Protalix Biotherapeutics net debt vs free cash flow
PLX Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -3.7

Protalix Biotherapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks